Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells. It is
not yet known which combination chemotherapy regimen is more effective for treating ovarian
epithelial cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus
paclitaxel with that of carboplatin plus docetaxel in treating patients who have ovarian
epithelial cancer.